European Clinical Research Alliance on Infectious Diseases

Grant number: 965313

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2026
  • Known Financial Commitments (USD)

    $36,122,690.34
  • Funder

    European Commission
  • Principal Investigator

    N/A

  • Research Location

    Belgium
  • Lead Research Institution

    STICHTING EUROPEAN CLINICAL RESEARCH ALLIANCE ON INFECTIOUS DISEASES
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

ECRAID-Base (European Clinical Research Alliance for Infectious Diseases) continues the activities of PREPARE, COMBACTE and ECRAID-Plan, which will lead to establishing ECRAID as an independent non-for-profit legal entity in December 2020. ECRAID-Base is the initial set of activities for ECRAID. As a European clinical research network ECRAID-Base will generate rigorous evidence to improve diagnosis, prevention and treatment of infections and to better respond to EID threats.. The network has already been successfully used during the COVID-19 pandemic, with valuable lessons learned. At the heart of ECRAID-Base are 6 perpetual studies; 5 observational studies in ICU (WP2), ER (WP3,4&5) and primary care (WP6), addressing infections relevant for AMR (VAP in WP2 & cUTI in WP3) and EID (ARI in WP4 & WP6, and Disease X in WP5). All will mature towards adaptive platform trials, with capability to rapidly respond to public health threats. These 5 studies will enroll around 20,000 patients per year. The sixth perpetual study is the Randomized Embedded Multifactorial Adaptive Platform (REMAP) for patients with severe CAP in ICU, with capability of rapid adaptation to new public health threats as demonstrated. In a response to COVID-19 the platform was (within 2 months) adapted with new COVID-19 treatment domains and enrolment of non-ICU patients, and the number active sites rapidly increased in 213 sites (June 4th) with 1084 patients enrolled (567 with COVID-19). Supportive to the clinical studies are work packages LAB (for laboratory support), DATA (for datamanagement and innovative epidemiological and statistical research), TRAIN (for training) and PREP (for improving responsiveness to new public health threats). ECRAID-Base, therefore, establishes a pan-European clinical research network to increase efficiency for testing and developing new diagnostic, preventive and/or therapeutic strategies and therapies and improving responsiveness to new public health thretbd

Publicationslinked via Europe PMC

Last Updated:5 hours ago

View all publications at Europe PMC

A comparison of frequentist and Bayesian approaches to the Personalised Randomised Controlled Trial (PRACTical)-design and analysis considerations.

Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial.

How to: share and reuse data-challenges and solutions from predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance project.

Tracking Candidemia Trends and Antifungal Resistance Patterns across Europe: An In-Depth Analysis of Surveillance Systems and Surveillance Studies.

Sex differences in post-acute neurological sequelae of SARS-CoV-2 and symptom resolution in adults after coronavirus disease 2019 hospitalization: an international multi-centre prospective observational study.

Modelling antimicrobial resistance transmission to guide personalized antimicrobial stewardship interventions and infection control policies in healthcare setting: a pilot study.

Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19.